RxDoctor Payments Data

James Cottom, DPM

Podiatrist · Sarasota, FLNPI 1720079163

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (38.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Arthrex at 50.6% of the total. Among podiatrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,758,666in general payments, 2019–2025

Across 740 payments — averaging $2376.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$890K
  • Vilex LLC$445K
  • Kerecis Limited$104K
  • Triad Life Sciences Inc.$95K
  • Fusion Orthopedics USA, LLC$38K
  • Integra Lifesciences Corporation$34K
  • plus $153K from 30 others
$97,218in research payments, 2019–2025

Across 26 payments — averaging $3739.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • BONE Support AB$41K
  • Integra Lifesciences Corporation$25K
  • Avitus Orthopaedics, Inc.$18K
  • Smith+Nephew$7K
  • Vilex LLC$6K
$37,763in ownership & investment interests, 2019–2025

Across 8 payments — averaging $4720.42 each. An ownership or investment interest held by the physician or an immediate family member.

  • Gramercy Extremity Orthopedics LLC$25K
  • Restor3d, Inc.$13K

What the payments were for

  • Royalty or licence$674,82738%
  • Consulting fees$626,00436%
  • Speaking & faculty fees$267,64115%
  • Travel & lodging$133,1408%
  • Food & beverage$14,0081%
  • Education$6,2000%
  • Ownership interest$9,6001%
  • Other$27,2482%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,758,666 in reported general payments places this provider in the 95th percentile of 588 podiatrist providers in Florida.

See all podiatrist providers in Florida

Medicare billing

Part B allowed, 2024
$218,258
Medicare patients
288
Services billed
2,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen54$809
Ondansetron Hcl38$222
Cephalexin31$216
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$39

Paid to pharmacies, not to this prescriber.

Other podiatrist in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →